Skip to content

Paediatric sarcoma, hybrid imaging & FAPI – Raising the diagnostic standard for paediatric sarcoma patients combining novel radiotracer FAPI and whole-body PET/MRI

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-524874-41-00
Enrollment
40
Registered
2026-08-28
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paediatric sarcoma

Brief summary

The ability of the nuclear medicine physician and the radiologist to accurately detect malignancy in [68Ga]Ga-FAPI-46 WB PET/MRI vs. SOC imaging.

Detailed description

Correlation of IHC of the FAP-antigen in tumour lesions and tumour FAP-expression using the radioactive tracer [68Ga]Ga-FAPI-46, Evaluation of patient and/or parent(s’) and experiences., Evaluation of the technical feasibility of implementation in clinical practice

Interventions

Sponsors

Rigshospitalet
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
The ability of the nuclear medicine physician and the radiologist to accurately detect malignancy in [68Ga]Ga-FAPI-46 WB PET/MRI vs. SOC imaging.

Secondary

MeasureTime frame
Correlation of IHC of the FAP-antigen in tumour lesions and tumour FAP-expression using the radioactive tracer [68Ga]Ga-FAPI-46, Evaluation of patient and/or parent(s’) and experiences., Evaluation of the technical feasibility of implementation in clinical practice

Outcome results

None listed

Source: EU CTIS · Data processed: Aug 29, 2026